ArticleNature communications2022
Synthetic glycans control gut microbiome structure and mitigate colitis in mice.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 60 citations in OpenAlex.
- Metabolic plasticity of the gut microbiome in response to diets differing in glycemic load in a randomized, crossover, controlled feeding study.The American journal of clinical nutrition · 2025Trial
- Guidelines for dietary fiber evaluation: A proposed standard integrating glycan structural diversity.Innovation (Cambridge (Mass.)) · 2026Article
- Synergistic synbiotic therapies for ulcerative colitis: mechanistic insights from multi-targeted pathways in animal models.Inflammopharmacology · 2026Review
- A montmorillonite-based oral fermentation system enables long-lasting in-situ biosynthesis to restore intestinal homeostasis.Nature communications · 2026Article
- Gut microbiome, stress and interventional strategies using hardy animals.Future science OA · 2025Review
- Microbial micronutrient sharing, gut redox balance and keystone taxa as a basis for a new perspective to solutions targeting health from the gut.Gut microbes · 2025Review
- The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development.Nature reviews. Drug discovery · 2025Review
- Chemical tools to study and modulate glycan-mediated host-bacteria interactions.Current opinion in chemical biology · 2025Review
- Article
- Role of a Precision Biotic Fed to Dekalb White Laying Hens at Peak Production.Animals : an open access journal from MDPI · 2025Article
- In vivo manipulation of human gut Bacteroides fitness by abiotic oligosaccharides.Nature chemical biology · 2025Article
- Effect of microbial diversity and their functions on soil nutrient cycling in the rhizosphere zone of Dahongpao mother tree and cutting Dahongpao.Frontiers in plant science · 2025Article
- Glycosidic linkages of fungus polysaccharides influence the anti-inflammatory activity in mice.Journal of advanced research · 2025Article
- Targeted discovery of gut microbiome-remodeling compounds for the treatment of systemic inflammatory response syndrome.mSystems · 2024Article
- Article
- The Gut Microbiome Advances Precision Medicine and Diagnostics for Inflammatory Bowel Diseases.International journal of molecular sciences · 2024Review
- Ulcerative colitis: molecular insights and intervention therapy.Molecular biomedicine · 2024Review
- Combining Liquid Chromatography and Cryogenic IR Spectroscopy in Real Time for the Analysis of Oligosaccharides.Analytical chemistry · 2024Article
- Evaluation Recovery of Ulcerative Colitis with aAdvanced biomedical research · 2024Article
- Regulatory effect of lactulose on intestinal flora and serum metabolites in colitis mice:Food chemistry: X · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 9 institutions in 2 countries.
Funding
Abstract
Relative abundances of bacterial species in the gut microbiome have been linked to many diseases. Species of gut bacteria are ecologically differentiated by their abilities to metabolize different glycans, making glycan delivery a powerful way to alter the microbiome to promote health. Here, we study the properties and therapeutic potential of chemically diverse synthetic glycans (SGs). Fermentation of SGs by gut microbiome cultures results in compound-specific shifts in taxonomic and metabolite profiles not observed with reference glycans, including prebiotics. Model enteric pathogens grow poorly on most SGs, potentially increasing their safety for at-risk populations. SGs increase survival, reduce weight loss, and improve clinical scores in mouse models of colitis. Synthetic glycans are thus a promising modality to improve health through selective changes to the gut microbiome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.